u DNA Plant Technology Corp., of Oakland, Calif., has signed a four-year research agreement with Panama-based Alida Marine Inc. todevelop genetically engineered pineapples to control ripening andextend the shelf life of the fruit. Under the terms of the agreement,Alida has purchased 2 million shares of stock in DNA PlantTechnology, which will have exclusive rights to the technology.u GenPharm International Inc., of Mountain View, Calif., has signed anagreement with Mollegaard Breeding and Research Centre, of Ejby,Denmark, to distribute the former's transgenic rat models in Europe.GenPharm's HLA-B27 transgenic rat is used as a model of humaninflammatory disease. They are raised by inserting the human HLA-B27 gene into fertilized one-cell rat eggs, causing mature rats todevelop lesions similar to those experienced in arthritis, psoriasis andinflammatory bowel disease.u Advanced Magnetics Inc., of Cambridge, Mass., has agreed to pay $1million to Bristol-Myers Squibb, of New York, to regain marketingrights to the former's magnetic resonance imaging contrast agent. Inaddition to the $1 million, Advanced Magnetics will pay up to $2.75million in royalties to Bristol-Myers Squibb, which will return awarrant for the purchase of 600,000 shares of Advanced Magneticsstock.
(c) 1997 American Health Consultants. All rights reserved.